Skip to main content

Table 3 Time-varying HR estimatesa from a fixed-effects NMA of RFS/DFS (p1 = 0, p2 = −1, scale, shape ×1) in patients with resected stage II–IV melanoma

From: Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis

Treatment Time points
12 months 24 months 36 months 48 months
NIVO vs. OBS/PBO 0.58 (0.43–0.77) 0.51 (0.33–0.80) 0.46 (0.26–0.86) 0.43 (0.21–0.91)
NIVO vs. DAB+TRAM 1.02 (0.71–1.47) 0.46 (0.27–0.78) 0.28 (0.14–0.59) 0.20 (0.08–0.49)
NIVO vs. PEM 1.19 (0.81–1.76) 1.06 (0.56–2.05) 0.96 (0.40–2.29) 0.88 (0.30–2.51)
NIVO vs. IPI (10 mg/kg) 0.69 (0.55–0.86) 0.66 (0.46–0.96) 0.65 (0.40–1.07) 0.64 (0.35–1.17)
NIVO vs. IPI (3 mg/kg) 0.75 (0.54–1.04) 0.93 (0.58–1.48) 1.06 (0.57–2.01) 1.16 (0.54–2.55)
NIVO vs. CHEM 0.63 (0.44–0.89) 0.53 (0.32–0.86) 0.47 (0.24–0.91) 0.42 (0.19–0.95)
NIVO vs. IFN 0.64 (0.48–0.86) 0.55 (0.36–0.88) 0.49 (0.27–0.93) 0.46 (0.22–0.97)
  1. aThe value in each cell represents the hazard ratio (95% credible interval) for the comparison of the treatments; bolded values are statistically significant at the 0.05 significance level
  2. CHEM other chemotherapy, DAB dabrafenib, DFS disease-free survival, HR hazard ratio, IFN interferon, IPI ipilimumab, NIVO nivolumab, NMA network meta-analysis, OBS observation, PBO placebo, PEM pembrolizumab, RFS recurrence-free survival, TRAM trametinib